Viridian Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell VRDN and other ETFs, options, and stocks.About VRDN
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis.
CEOStephen Frank Mahoney
CEOStephen Frank Mahoney
Employees143
Employees143
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2006
Founded2006
Employees143
Employees143
VRDN Key Statistics
Market cap1.12B
Market cap1.12B
Price-Earnings ratio-3.37
Price-Earnings ratio-3.37
Dividend yield—
Dividend yield—
Average volume822.91K
Average volume822.91K
High today$13.85
High today$13.85
Low today$13.26
Low today$13.26
Open price$13.61
Open price$13.61
Volume1.03M
Volume1.03M
52 Week high$27.20
52 Week high$27.20
52 Week low$9.90
52 Week low$9.90
Analyst ratings
88%
of 17 ratingsBuy
88.2%
Hold
11.8%
Sell
0%
People also own
Based on the portfolios of people who own VRDN. This list is generated using Robinhood data, and it’s not a recommendation.